Brought to you by 
Kite Pharma, Inc.
http://www.kitepharma.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kite Pharma, Inc.
COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Kite Pharma EU
- T-Cell Factory B.V. (TCF)